1. Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial Watch: adoptively transferred cells for anticancer immunotherapy. OncoImmunology. 2017;6(11):e1363139. https://doi.org/10.1080/2162402X.2017.1363139 https://pubmed.ncbi.nlm.nih.gov/29147628 
2. Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, et al. Trial Watch: immunostimulation with Toll-like receptor agonists in cancer therapy. OncoImmunology. 2015;5(3):e1088631. https://doi.org/10.1080/2162402X.2015.1088631 https://pubmed.ncbi.nlm.nih.gov/27141345 
3. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-9. https://doi.org/10.1038/nature10673 https://pubmed.ncbi.nlm.nih.gov/22193102 
4. Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, et al. Trial Watch: immunotherapy plus radiation therapy for oncological indications. OncoImmunology. 2016;5(9):e1214790. https://doi.org/10.1080/2162402X.2016.1214790 https://pubmed.ncbi.nlm.nih.gov/27757313 
5. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nat Rev Clin Oncol. 2011;8(10):577-85. https://doi.org/10.1038/nrclinonc.2011.116 https://pubmed.ncbi.nlm.nih.gov/21808266 
6. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341(6151):1192-8. https://doi.org/10.1126/science.1241145 https://pubmed.ncbi.nlm.nih.gov/24031011 
7. Dillman RO, Cornforth AN, McClay EF, Depriest C. Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. Melanoma Manag. 2019;6(2):MMT20. https://doi.org/10.2217/mmt-2018-0010 https://pubmed.ncbi.nlm.nih.gov/31406564 
8. Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, et al. Trial Watch: peptide-based anticancer vaccines. OncoImmunology. 2015;4(4):e974411. https://doi.org/10.4161/2162402X.2014.974411 https://pubmed.ncbi.nlm.nih.gov/26137405 
9. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-27. https://doi.org/10.1056/NEJMoa1012863 https://pubmed.ncbi.nlm.nih.gov/21631324 
10. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-17. https://doi.org/10.1056/NEJMoa1407222 https://pubmed.ncbi.nlm.nih.gov/25317870 
11. Newick K, Moon E, Albelda SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics. 2016;3:16006. https://doi.org/10.1038/mto.2016.6 https://pubmed.ncbi.nlm.nih.gov/27162934 
12. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-81. https://doi.org/10.1038/nri3191 https://pubmed.ncbi.nlm.nih.gov/22437939 
13. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49-60. https://doi.org/10.1016/j.immuni.2013.07.002 https://pubmed.ncbi.nlm.nih.gov/23890063 
14.          Perica K, Varela JC, Oelke M, Schneck J. Adoptive T Cell Immunotherapy for Cancer. Rambam Maimonides Med J. 2015;6(1):e0004. https://doi.org/10.5041/RMMJ.10179 https://pubmed.ncbi.nlm.nih.gov/25717386 
15. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21(1):807-39. https://doi.org/10.1146/annurev.immunol.21.120601.141135 https://pubmed.ncbi.nlm.nih.gov/12615893 
16. Magalhaes I, Carvalho-Queiroz C, Hartana CA, Kaiser A, Lukic A, Mints M, et al. Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. Expert Opin Biol Ther. 2019;19(8):811-27. https://doi.org/10.1080/14712598.2019.1608179 https://pubmed.ncbi.nlm.nih.gov/30986360 
17. June C. Promises and challenges of engineered T cell therapies. Hum Gene Ther. 2009;20(11):1361. 
18. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339(6117):286-91. https://doi.org/10.1126/science.1232227 https://pubmed.ncbi.nlm.nih.gov/23329041 
19. Engblom C, Pfirschke C, Zilionis R, Da Silva Martins J, Bos SA, Courties G, et al. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF high neutrophils. Science. 2017;358(6367):eaal5081. https://doi.org/10.1126/science.aal5081 https://pubmed.ncbi.nlm.nih.gov/29191879 
20. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938-45. https://doi.org/10.1038/nm.3909 https://pubmed.ncbi.nlm.nih.gov/26193342 
21. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309-22. https://doi.org/10.1016/j.ccr.2012.02.022 https://pubmed.ncbi.nlm.nih.gov/22439926 
22. Syn NL, Teng MW, Mok TS, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18(12):e731-41. https://doi.org/10.1016/S1470-2045(17)30607-1 https://pubmed.ncbi.nlm.nih.gov/29208439 
23. Chandran SS, Klebanoff CA. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev. 2019;290(1):127-47. https://doi.org/10.1111/imr.12772 https://pubmed.ncbi.nlm.nih.gov/31355495 
24. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86(15):1159-66. https://doi.org/10.1093/jnci/86.15.1159 https://pubmed.ncbi.nlm.nih.gov/8028037 
25. Geukes Foppen MH, Donia M, Svane IM, Haanen JB. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol Oncol. 2015;9(10):1918-35. https://doi.org/10.1016/j.molonc.2015.10.018 https://pubmed.ncbi.nlm.nih.gov/26578452 
26. Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol Immunother. 2019;68(5):773-85. https://doi.org/10.1007/s00262-019-02307-x https://pubmed.ncbi.nlm.nih.gov/30747243 
27. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676-80. https://doi.org/10.1056/NEJM198812223192527 https://pubmed.ncbi.nlm.nih.gov/3264384 
28. Janeway CA. How the immune system protects the host from infection. Microbes Infect. 2001;3(13):1167-71. https://doi.org/10.1016/S1286-4579(01)01477-0 https://pubmed.ncbi.nlm.nih.gov/11709297 
29. Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol. 2012;12(9):669-77. https://doi.org/10.1038/nri3279 https://pubmed.ncbi.nlm.nih.gov/22918468 
30. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566-81. https://doi.org/10.1038/nrc.2016.97 https://pubmed.ncbi.nlm.nih.gov/27550819 
31. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-9. https://doi.org/10.1126/science.1129003 https://pubmed.ncbi.nlm.nih.gov/16946036 
32. Bialer G, Horovitz-Fried M, Ya’acobi S, Morgan RA, Cohen CJ. Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol. 2010;184(11):6232-41. https://doi.org/10.4049/jimmunol.0902047 https://pubmed.ncbi.nlm.nih.gov/20427762 
33. Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol. 2010;184(11):6223-31. https://doi.org/10.4049/jimmunol.0902055 https://pubmed.ncbi.nlm.nih.gov/20483785 
34. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007;67(8):3898-903. https://doi.org/10.1158/0008-5472.CAN-06-3986 https://pubmed.ncbi.nlm.nih.gov/17440104 
35. Voss RH, Willemsen RA, Kuball J, Grabowski M, Engel R, Intan RS, et al. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol. 2008;180(1):391-401. https://doi.org/10.4049/jimmunol.180.1.391 https://pubmed.ncbi.nlm.nih.gov/18097040 
36. Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. https://doi.org/10.1126/science.aba7365 https://pubmed.ncbi.nlm.nih.gov/32029687 
37. Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017;130(18):1985-94. https://doi.org/10.1182/blood-2017-06-791202 https://pubmed.ncbi.nlm.nih.gov/28860210 
38. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-102. https://doi.org/10.1182/blood-2010-04-281931 https://pubmed.ncbi.nlm.nih.gov/20668228 
39. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-98. https://doi.org/10.1158/2159-8290.CD-12-0548 https://pubmed.ncbi.nlm.nih.gov/23550147 
40. Siegler EL, Kim YJ, Chen X, Siriwon N, Mac J, Rohrs JA, et al. Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers. Mol Ther. 2017;25(12):2607-19. https://doi.org/10.1016/j.ymthe.2017.08.010 https://pubmed.ncbi.nlm.nih.gov/28919377 
41. Sadelain M. Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy. Annu Rev Cancer Biol. 2017;1(1):447-66. https://doi.org/10.1146/annurev-cancerbio-050216-034351 
42. Posey AD, Clausen H, June CH. Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety. Immunity. 2016;45(5):947-8. https://doi.org/10.1016/j.immuni.2016.10.015 https://pubmed.ncbi.nlm.nih.gov/27851918 
43. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99(6):2009-16. https://doi.org/10.1182/blood.V99.6.2009 https://pubmed.ncbi.nlm.nih.gov/11877273 
44. Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther. 1998;5(6):401-7. https://pubmed.ncbi.nlm.nih.gov/9917095 
45. Sadelain M.. CAR therapy: the CD19 paradigm. J Clin Invest. 2015;125(9):3392-400. https://doi.org/10.1172/JCI80010 https://pubmed.ncbi.nlm.nih.gov/26325036 
46. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212-21. https://doi.org/10.1182/blood-2018-12-893396 https://pubmed.ncbi.nlm.nih.gov/30808634 
47. Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric Antigen Receptor Therapy for B-cell Malignancies. J Cancer. 2011;2:331-2. https://doi.org/10.7150/jca.2.331 https://pubmed.ncbi.nlm.nih.gov/21716851 
48. Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408-14. https://doi.org/10.1038/s41591-019-0549-5 https://pubmed.ncbi.nlm.nih.gov/31477906 
49. Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270-80. https://doi.org/10.1038/s41591-019-0737-3 https://pubmed.ncbi.nlm.nih.gov/31959992 
50. D’Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2020;34(1):21-34. https://doi.org/10.1038/s41375-019-0669-4 https://pubmed.ncbi.nlm.nih.gov/31780814 
51. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985-1005. https://doi.org/10.1038/s41375-020-0734-z https://pubmed.ncbi.nlm.nih.gov/32055000 
52. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010;33(1):1-7. https://doi.org/10.1097/CJI.0b013e3181b88ffc https://pubmed.ncbi.nlm.nih.gov/19952961 
53. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-5. https://doi.org/10.1126/science.aar4060 https://pubmed.ncbi.nlm.nih.gov/29567705 
54. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202-6. https://doi.org/10.1038/s41588-018-0312-8 https://pubmed.ncbi.nlm.nih.gov/30643254 
55. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. https://doi.org/10.3322/caac.21551 https://pubmed.ncbi.nlm.nih.gov/30620402 
56. Fagerberg L, Jonasson K, von Heijne G, Uhlén M, Berglund L. Prediction of the human membrane proteome. Proteomics. 2010;10(6):1141-9. https://doi.org/10.1002/pmic.200900258 https://pubmed.ncbi.nlm.nih.gov/20175080 
57. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. https://doi.org/10.1126/science.1260419 https://pubmed.ncbi.nlm.nih.gov/25613900 
